Video

Ari Green, MD

Publish date: April 5, 2018

Dr. Green, Chief of the Division of Neuroinflammation and Glial Biology at the University of California, San Francisco, discusses the development of potential remyelinating therapies and a recent trial of clemastine fumarate in patients with multiple sclerosis and chronic demyelinating optic neuropathy.

 

Recommended Reading

Natalizumab May Be Associated With Increased Disease Activity During Pregnancy
MDedge Neurology
Siponimod trial ‘first’ to show delayed disability in secondary progressive MS
MDedge Neurology
Are Complementary and Alternative Treatments Effective for MS?
MDedge Neurology
Frankincense extract may reduce disease activity in relapsing-remitting MS
MDedge Neurology
Extended-Interval Dosing of Natalizumab Is Associated With Reduced PML Risk
MDedge Neurology
MicroRNA Could Be a Biomarker of MS
MDedge Neurology
Patients With MS May Not Receive Appropriate Medicines From Primary Care Doctors
MDedge Neurology
What Is the Mechanism of Alemtuzumab-Induced Autoimmunity?
MDedge Neurology
High Dose of Novel Compound Shows Promise for Relapsing-Remitting MS
MDedge Neurology
Clean-Surfaced Nanocrystalline Gold May Promote Remyelination
MDedge Neurology

Related Articles